 A STUDY TO EVALUATE THE EFFICACY AND SAFETYTOLERABILITY OF SUBCUTANEOUS TILDRAKIZUMAB SCH 900222MK-3222 IN PARTICIPANTS WITH MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS FOLLOWED BY A LONG-TERM EXTENSION STUDY MK-3222-011: 